This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 07
  • /
  • Laquinomod (Active Biotech/Teva) is filed at EMA f...
Drug news

Laquinomod (Active Biotech/Teva) is filed at EMA for Multiple Sclerosis

Read time: 1 mins
Last updated: 18th Jul 2012
Published: 18th Jul 2012
Source: Pharmawand
Active Biotech/Teva has announced that the European Medicines Agency (EMA) has completed the validation process for the marketing authorization application of laquinimod for the treatment of relapsing-remitting Multiple Sclerosis.The submission is supported by a pooled analysis of data from the two global Phase III clinical trials in RRMS involving more than 2,400 patients treated for two years, the ALLEGRO and BRAVO trials.
Brain nerve cells
Brain nerve cells
Learning Zone

Multiple Sclerosis (MS) Learning Zone

Choosing the right treatment is critical to managing multiple sclerosis (MS). Consider your options with the latest data from over 40 MS clinical trial and congress resources.

Read more
How do you prefer to access medical updates and information?
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Blue test tubes arranged in a line, disappearing into the background
Drug news
Moderna reports H5 Flu data
Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.
Read more
Drug news
Cibotercept in PAH ends

Published: 30th May 2025

Read more
Drug news
Khindivi cleared for pediatrics

Published: 30th May 2025

Read more
See all news